NCT02725567View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 2, 2016

Primary Completion Date

June 28, 2022

Study Completion Date

June 28, 2022

Conditions

Cystic Fibrosis

Interventions

DRUG

IVA

Granules in sachet for oral administration.

Trial Locations (23)

Unknown

Birmingham

Palo Alto

Atlanta

Chicago

Indianapolis

Baltimore

Boston

Kansas City

Columbus

Philadelphia

Houston

Seattle

Madison

Parkville

South Brisbane

Westmead

Toronto

Dublin

Edinburgh

Leicester

London

Manchester

Oxford

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02725567 - A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation | Biotech Hunter | Biotech Hunter